- Home
- BANC vs ARQT Comparison
BANC vs ARQT Comparison
Compare BANC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANC | ARQT |
|---|---|---|
| Founded | 1941 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BANC | ARQT |
|---|---|---|
| Price | $19.49 | $26.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $21.83 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 3.6M | 1.4M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 125.00 | 88.79 |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $1,818,792,000.00 | $376,072,000.00 |
| Revenue This Year | $13.93 | $34.85 |
| Revenue Next Year | $8.03 | $29.39 |
| P/E Ratio | ★ $17.08 | $859.67 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $15.17 | $14.81 |
| 52 Week High | $21.93 | $31.77 |
Technical Indicators
Market Signals| Indicator | BANC | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 48.83 |
| Support Level | $18.15 | $24.96 |
| Resistance Level | $21.60 | $27.99 |
| Average True Range (ATR) | 0.62 | 1.31 |
| MACD | -0.14 | -0.28 |
| Stochastic Oscillator | 30.77 | 39.29 |
Price Performance
Historical ComparisonAbout BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.